LRRTM2

Across TCGA pan-cancer cohorts, LRRTM2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of LRRTM2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where LRRTM2 RNA is repressed in tumor relative to normal tissue. In most cancer types LRRTM2 is over-expressed in tumor, although a few such as THCA and COAD show the opposite, repressed pattern.

THCA, HNSC, and COAD are the cancer types where LRRTM2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LRRTM2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	−0.292	<.001	10	view →
HNSC	All	III,IV	+0.239	<.001	10	view →
COAD	Female	All	−0.248	<.001	9	view →
KIRP	Male	All	−0.305	<.001	7	view →
BRCA	All	III,IV	−1.043	<.001	6	view →
UCEC	All	All	−0.326	<.001	6	view →
KICH	All	All	−0.341	<.001	5	view →
KIRC	All	II,III,IV	−0.184	.006	5	view →
LUAD	Female	II,III,IV	−0.580	<.001	3	view →
LUSC	All	II,III,IV	−0.313	.017	2	view →
READ	All	All	−0.290	.013	2	view →
STAD	Male	IV	−0.200	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

LRRTM2–THCA

Open the THCA breakdown →